GeoVax Labs, Inc. (OTCMKTS:GOVX)’s Step Down Turns Into A Nose Dive

It now seems that GeoVax Labs, Inc. (OTCMKTS:GOVX)’s crash on Thursday was only a harbinger of an even greater downfall to come. Yesterday, the ticker crashed 17.95%, further pulled down by the latest 8-K full of developments on GOVX‘s toxic debts.

Although using the word “hype” to describe the Ebola-related surge of interest that pushed GOVX up the charts on Oct. 2, Oct. 7 and Oct.13 sounds inappropriate, it would be accurate to say that the company managed to exploit it rather well.

However, heads inevitably cool after a while and if the company has nothing going for it by the time they do, stock prices usually crash horribly.

This is precisely what is happening with GOVX now. The company managed to catch the rocker to the top of the charts ona surge of publicity driven activity, but it was clear enough to everyone involved that it was a risky move and the ticker’s ascent wouldn’t last. Add the fact that the actual product the company could eventually come up with is scheduled for release approximately a year and a half from now in the best case scenario, and it becomes obvious that things were bound to get ugly pretty quickly.

And they did, once the news

 that Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. were each capable of dumping more than 2.6 million shares of GOVX common stock on the market, should they see fit. The fact that these shares could be acquired by said parties for a price of $0.075 a pop seems to have horrified investors, but that state of developments didn’t last all that long either.

At the moment, GVOX is 15.63% up in today’s early trading.